Melanoma Institute part of $14m melanoma project grant
25 March 2015
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
The research, funded as part of the National Health and Medical Research Council (NHMRC) Program scheme, will commence in 2016 and will be administered through Macquarie University in Sydney. The team’s investigators are largely based at the University of Sydney, as well as the Centenary Institute, the Westmead Millennium Institute for Medical Research, and the QIMR Berghofer Medical Research Institute.
All investigators are part of MIA, the world’s largest cancer centre dedicated to research and treatment of melanoma, and have been linked as a NHMRC Program since 2006. Treating 1900 new melanoma patients annually, the MIA’s repository of clinical research data and melanoma biospecimens is the largest in the world.
Lead researcher Professor Rick Kefford from MIA and Macquarie University said the project had real prospects of accelerating prevention and early detection of melanoma.
“In this era of rapid change the program could make realistic progress towards a cure of metastatic disease,” Professor Kefford said.
MIA tumour samples and data from people receiving targeted and immune treatments for melanoma are driving these promising advances. The Program has also recruited thousands of people from the community, and families with a strong history of melanoma, to lead discovery of melanoma risk genes.
“In the last few years our program has helped drive large-scale genomic analysis of melanoma, and this will continue to be a cornerstone of our research,” says Professor Graham Mann of MIA, Westmead Millennium Institute and the University of Sydney. “These approaches have already been highly successful, and we have great hopes for better prevention, detection and treatment of melanoma in the future,” he said.
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.